Aradigm Corporation Initiates Phase 2 Study of Inhaled Liposomal Ciprofloxacin for Cystic Fibrosis

HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTCBB:ARDM) today announced it has initiated a Phase 2 study of its proprietary inhaled liposomal formulation of ciprofloxacin in patients with cystic fibrosis. This safety and efficacy study follows the successful completion of a Phase 1 safety, tolerability and pharmacokinetics trial in healthy volunteers and the previously executed preclinical toxicology program.
MORE ON THIS TOPIC